指南与共识肾小球疾病肾移植

免疫介导性肾脏病患者COVID-19疫苗接种建议

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.
指南 / 共识 · Nephrol Dial Transplant · 2021-03-09

Coronavirus Disease 19 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of SARS-CoV-2 infections.…

要点

  • 应监测接种后体液免疫应答,即使无中和抗体,足够的细胞免疫也可能减轻COVID-19严重程度。
  • 使用CD20耗竭剂的患者疫苗应答可能降低,需讨论改善疫苗应答的策略。
  • 保持社交距离和防护措施仍重要,因疫苗不能完全预防冠状病毒感染。

核心结论

  • 免疫介导性肾脏病患者接种COVID-19疫苗需权衡利弊,应开展上市后监测评估疫苗应答与疾病活动性。
  • 部分疫苗候选者诱导的信号通路可能促进自身免疫性肾病,如I型干扰素在系统性红斑狼疮中。
  • 效力估计暂支持使用BNT162b2、mRNA-1273或Gam-COVID-Vac等特定COVID-19疫苗。

主要发现

  • 部分疫苗候选者诱导的信号通路可能促进自身免疫性肾脏疾病,例如I型干扰素在系统性红斑狼疮中的作用。
  • 效力估计暂支持使用BNT162b2、mRNA-1273或Gam-COVID-Vac等特定COVID-19疫苗。
  • 使用CD20耗竭剂后预计疫苗应答降低,需与患者讨论改善疫苗应答的策略。
  • 即使缺乏中和抗体,足够的细胞免疫应答也可能保护患者、减轻COVID-19严重程度。
  • 保持社交距离和防护措施仍然重要,因为并非所有疫苗都能完全预防冠状病毒感染。

关键数值与推荐

  • 应通过适当检测方法监测接种后体液免疫应答。
  • 应开展上市后监测以评估不同疫苗平台的疫苗应答率(体液和细胞)及接种后疾病活动性。

临床怎么用

  • 对免疫介导性肾脏病患者接种COVID-19疫苗前应评估免疫抑制方案,尤其是CD20耗竭剂的使用。
  • 接种后应监测体液免疫应答,并考虑细胞免疫保护作用。
  • 应与患者讨论疫苗应答可能降低及改善策略,同时强调继续采取防护措施。
  • 向患者提供深入信息以减少疫苗犹豫。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus Disease 19 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of SARS-CoV-2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs. Here, members of the Immunonephrology Working Group (IWG) of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) discuss thirteen frequently-asked questions regarding safety and efficacy of the most promising vaccine candidates. Post-marketing surveillance should be performed to estimate the rate of vaccine response (humoral and cellular) of different vaccine platforms, and surveillance of disease activity following administration of COVID-19 vaccines. Some of the candidates induce signaling pathways which also promote autoimmune kidney diseases, e.g. type I interferons in systemic lupus erythematosus. Efficacy estimates would thus far favor the use of selected COVID-19 vaccines, such as BNT162b2, mRNA-1273 or Gam-COVID-Vac. Humoral immune response after vaccination should be monitored using appropriate assays. Even in the absence of neutralizing antibodies patients might be protected by a sufficient cellular immune response capable to reduce severity of COVID-19. A reduced vaccine response after the use of CD20-depleting agents is anticipated, and it is particularly important to discuss strategies to improve vaccine response with these patients. Distancing and shielding measures remain important as not all vaccines fully protect from coronavirus infection. In-depth information about the most pressing vaccine questions is essential to reduce vaccine hesitancy of patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kronbichler A, Anders HJ, Fernandez-Juárez GM, et al. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases. Nephrol Dial Transplant. 2021. PMID: 33693778. doi:10.1093/ndt/gfab064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。